IPL Team Member Presentations

News/Blog Body

Interventional Psychiatry team members share the lab's work at various conferences around the state and nation. We are excited to share our research with the larger community!

IPL Researcher Ahmed Sakr & Post-Doc Butool Durrani at Neuromodulation 2024

Interventional Psychiatry Lab Researcher, Dr. Ahmed Sakr and Post-Doc, Dr. Butool Durrani, presented "Exploring Therapeutic Mechanisms: Neuroimaging Insights into Focal Electrically Administered Seizure Therapy (FEAST) for Treatment-Resistant Depression" at the 2024 Neuromodulation Symposium.

FEAST is a novel treatment approach used for treatment-resistant major depressive disorder (MDD). Unlike electroconvulsive therapy (ECT), it aims at delivering focal electrical stimulation to the right frontal lobe thus avoiding the hippocampi. The team questioned whether resting-state functional magnetic resonance imaging (rs-fMRI) might elucidate FEAST’s mechanism of action. As additional participants complete scanning and treatment, this important data analysis will continue.

Co-authors included: R. Hermosillo, R. Johnson, J. Chaikind, T. Madison, K. Weldon, C. Differding, M. Hazimeh, M. Shahdin, S. Nelson, D. Fair, Z. Nahas

Thank you: Cash, Maya, Maryam and Rachel, for your work with data collection; Thomas, Kim and Steve for your data analysis support; Drs. Robert Hermosillo, Jeremy Chaikind, Damien Fair and Ziad Nahas, for your expertise!

 

Thank you, Ahmed and Butool, for presenting this important work!

Ahmed Sakr and Butool Durrani at Neuromodulation 2024

IPL Post-Doc Maya Hazimeh at ADAA 2024

Interventional Psychiatry Lab Post Doc, Dr. Maya Hazimeh, presented "ECT Equity: Disparities in ECT Access in a Tertiary Medical Center" at the ADAA 2024 Annual Conference in Boston, MA in April.

This poster demonstrated results from a retrospective analysis of ECT use and highlighted populations that do and do not receive ECT. Primary findings from this sample include: ECT usage increases with age; patients of color underutilize ECT; ECT is covered at a higher proportion by governmental insurance compared to private insurance. Secondarily, in this sample, patients with a prior successful experience with ECT were more likely to try it again, as opposed to patients with previous side effects. Some patients still have fear and misconception around ECT, and it is necessary to spread awareness of the benefits of ECT. 

Future work will involve a comparison with another medical center's utilization in the same time period.

Co-Authors included: S Wilson, RA Johnson, R Abu Ayed, N Buhta, A Bhagia, & Z Nahas

 

Maya Hazimeh at ADAA

Thank you, Maya, for presenting this important work!

Thank you, Rebecca, Nicholas, Alicia and Rachel, for your work with data quality!

Thank you, Drs. Saydra Wilson and Ziad Nahas, for your expertise!

Neuromodulation Symposium April 2023

Rebecca AbuAyed and Cash Differding present ketamine research at the Neuromodulation Symposium, April 2023
Emily Gears presents ECT research at the Neuromodulation Symposium, April 2023
Maya Hazimeh presents ECT equity research at the Neuromodulation Symposium, April 2023
Ahmed Sakr presents PCS research at the Neuromodulation Symposium, April 2023
Sina Shirinpour presents efield modeling research at the Neuromodulation Symposium, April 2023

The Interventional Psychiatry Lab attended the Neuromodulation Symposium on April 20-21, 2023. The team and partners presented five posters highlighting results of some of our latest research projects. Congratulations to the team, and thank you for sharing your work!

IPL CRC Anila Bano at 2023 ADAA

Interventional Psychiatry Lab Clinical Research Coordinator, Anila Bano, presented "TMS + CBT for Treatment-Resistant Depression with Comorbid Anxiety Disorders: A Case Series" at the ADAA 2023 Annual Conference in Washington DC earlier this month. 

Anila worked with Dr. Sabine Schmid to explore the course of TMS + CBT in three patients with treatment resistant depression (TRD) receiving services at the Interventional Psychiatry clinic. TMS refers to Transcranial Magnetic Stimulation, while CBT refers to Cognitive Behavioral Therapy. They conclude that comprehensive diagnostic assessment of lifetime comorbid anxiety disorders may help identify underlying (or primary) anxiety disorders and their role in individual presentations of TRD. Additionally, exact intervention strategies should be informed by the etiology of etiology and history of response to prior biological and psychosocial treatments. Finally, modifications of TMS + CBT for TRD with comorbid anxiety disorders may be needed in terms of sequencing and duration of CBT vs. TMS.

Co-authors included: CD Freilich, R Brower, RA Johnson, AB Herman, S Wilson, and Z Nahas

 

 

 

Thank you, Anila, for sharing this project at ADAA!

Anila Bano at ADAA Conference